ISCT

Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference

Retrieved on: 
Mercredi, mai 29, 2024
Patient, Cell, Doctor of Philosophy, Ori, Biology, ISCT, Automation, Organization, International Society, CGT, CSO, Workflow, IRO, Freedom, GMP, Pharmaceutical industry

The company today revealed the IRO platform at ISCT 2024 , International Society for Cell & Gene Therapy’s 30th annual conference, in Vancouver, British Columbia.

Key Points: 
  • The company today revealed the IRO platform at ISCT 2024 , International Society for Cell & Gene Therapy’s 30th annual conference, in Vancouver, British Columbia.
  • It is estimated that more than 95% of patients are left without access to cell and gene therapies1.
  • Ori has developed the IRO platform as part of their mission to enable widespread patient access to life-saving cell and gene therapies.
  • The IRO platform automates better biology, accelerates therapy development, and enables therapy developers to scale their products' clinical and commercial impact.

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Retrieved on: 
Mercredi, mai 29, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, EBV, Patient, Cell, Epstein–Barr virus, Phenotype, ISCT, Toxicity, SLE, Cytokine, CD19, International Society, ATRA, Cancer, Autoimmunity, PDT, IL-6, NHL, Inflammation, Lupus nephritis, Annual general meeting, Vaccine

Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.

Key Points: 
  • Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.
  • The data will be presented in a poster session at the International Society for Cell & Gene Therapy (ISCT) 2024 Annual Meeting taking place May 29 to June 1, 2024, in Vancouver, Canada.
  • ATA3219 consists of allogeneic CD19-directed CAR EBV T cells that have been optimized to offer a potential best-in-class profile and off-the-shelf availability.
  • “We are pleased to share promising preclinical data that shows ATA3219 mediates robust B-cell depletion against SLE and multiple sclerosis patient derived immune cells.

NMDP BioTherapies To Present Data at ISCT 2024 on the Stability of Infectious Disease Marker Analytes During Donor Qualification for Allogeneic Cell Therapies

Retrieved on: 
Mardi, mai 28, 2024
Health, Infectious Diseases, Genetics, Research, Science, Pharmaceutical, Biotechnology, Patient, Cell, ISCT, Organization, Laboratory, Product management, International Society, Collection, Centrifugation, Match, Antibody, NMDP, Vaccine

NMDP BioTherapies℠ (formerly known as Be The Match BioTherapies), a leader in cell and gene therapy development support, will present a poster at this year’s International Society for Cell & Gene Therapy annual meeting in Vancouver, Canada (ISCT 2024 ) sharing results of a study of the impacts of delayed whole blood processing on the stability of infectious disease marker analytes during donor qualification for allogeneic cell therapies.

Key Points: 
  • NMDP BioTherapies℠ (formerly known as Be The Match BioTherapies), a leader in cell and gene therapy development support, will present a poster at this year’s International Society for Cell & Gene Therapy annual meeting in Vancouver, Canada (ISCT 2024 ) sharing results of a study of the impacts of delayed whole blood processing on the stability of infectious disease marker analytes during donor qualification for allogeneic cell therapies.
  • Results of the study indicate that leveraging blood processing parameters for stability of metabolites may create artificially stringent preanalytical requirements, such as timelines between sample collection and centrifugation.
  • “Delayed sample processing when leveraging centralized testing laboratories can be a difficult reality of today’s donor qualification process for allogeneic cell therapies,” said Dr. Joy Aho, Director of Product Management at NMDP BioTherapies.
  • With access to donors and cord blood units from the NMDP Registry℠, which is the world’s most diverse registry, and an extensive collection network, NMDP BioTherapies provides a wide variety of cell sourcing options for developers of allogeneic cell and gene therapies so that they can expand treatment options for patients with life-threatening or debilitating diseases.

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

Retrieved on: 
Lundi, mai 20, 2024
Cell, Doctor of Philosophy, ISCT, Research and development, Translation, Clinical trial, International Society, Leber congenital amaurosis, Vaccine, Annual general meeting, BLA, MAA, LCA, PDT, Pharmaceutical industry

“I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay.

Key Points: 
  • “I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay.
  • Attendees can participate in robust debates, collaborate on developing solutions to sector challenges, and join conversations advancing the field of cell and gene therapy.
  • The OCU400 Phase 3 liMeliGhT clinical trial is currently underway and on track to meet the Company’s 2026 BLA and MAA approval targets.
  • OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication.

Xcell Biosciences to Showcase Future of Cell Manufacturing at ISCT 2024

Retrieved on: 
Mercredi, mai 22, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Health Technology, Other Science, Medical Devices, Research, Genetics, Science, Clinical Trials, Cell, ISCT, University, Tumor microenvironment, International Society, Conference, AVATAR, CGMP

Xcell Biosciences Inc. (Xcellbio), an innovative technology company focused on cell and gene therapy manufacturing applications, today announced its speaker lineup and activities for the upcoming ISCT 2024, the annual meeting of the International Society for Cell & Gene Therapy, taking place May 29 – June 1 in Vancouver, British Columbia.

Key Points: 
  • Xcell Biosciences Inc. (Xcellbio), an innovative technology company focused on cell and gene therapy manufacturing applications, today announced its speaker lineup and activities for the upcoming ISCT 2024, the annual meeting of the International Society for Cell & Gene Therapy, taking place May 29 – June 1 in Vancouver, British Columbia.
  • Along with AmplifyBio and the University of Virginia, Xcellbio will offer poster presentations of its AVATAR technology in T cell manufacturing and analytical applications.
  • Conference attendees may visit the booth to see the AVATAR Foundry system and experience a live demonstration of the instrument.
  • In addition, information about participating in the expanded beta access program for the AVATAR Foundry system will be available.

AmplifyBio and Xcell Biosciences Announce Partnership to Manufacture Solid Tumor-Targeting TCR-T Cell Therapy

Retrieved on: 
Lundi, mai 20, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Genetics, Clinical Trials, Science, Engineering, Biotechnology, Stem Cells, Health, Manufacturing, Partnership, Patient, Cell, ISCT, TME, International Society, IND, TCR, AVATAR, Neoplasm, Incubator, Tumor microenvironment, Poster, CGMP, Vaccine

“Current cell therapies have been highly effective for liquid tumors, but little progress has been made for the vast majority of patients with solid tumors.

Key Points: 
  • “Current cell therapies have been highly effective for liquid tumors, but little progress has been made for the vast majority of patients with solid tumors.
  • Its AVATAR Foundry platform is a cGMP cell therapy manufacturing platform that delivers novel capabilities for improving the potency of cell and gene therapies.
  • In this partnership, scientists from AmplifyBio will work with the Xcellbio team to develop novel cell therapy manufacturing methods based on the AVATAR Foundry platform.
  • An IND filing is expected next year to target human papillomavirus-positive (HPV+) tumors using an engineered TCR therapy.

Takara Bio Launches First Commercial Dissolvable Microfluidic Lentiviral Transduction Enhancer

Retrieved on: 
Lundi, mai 6, 2024
Research, Medical Supplies, Genetics, Health Technology, Biotechnology, Other Health, Health, Other Science, Science, School, University, International Society, North Carolina State University, Cell, Biomedical engineering, Abstract, UCL, Biomedicine, Lentivirus, Booth, Gene, Society, ISCT, Associate, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.
  • With an easy, walkaway workflow, the Lenti-X Transduction Sponge achieves high transduction efficiency in any cell type, enabling downstream research applications in the gene and cell therapy space.
  • “The Lenti-X Transduction Sponge will transform the viral transduction landscape with its simple yet elegant design,” said Carol Lou, President & CEO of Takara Bio USA.
  • At ISCT, attendees can engage with Takara Bio during the poster presentation (Abstract #1133) and view the Lenti-X Transduction Sponge at Booth #721.

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Retrieved on: 
Mercredi, mai 8, 2024
SNAP, University, Cancer, International Society, Infection, Cell, Research, Gene, ISCT, Therapy, Autoimmunity, NK

In Q3 of 2023, Coeptis expanded its exclusive license agreement with the University of Pittsburgh for SNAP-CAR to include natural killer (NK) cells.

Key Points: 
  • In Q3 of 2023, Coeptis expanded its exclusive license agreement with the University of Pittsburgh for SNAP-CAR to include natural killer (NK) cells.
  • Backed by research performed in conjunction with the University of Pittsburgh and Deverra Therapeutics, allogeneic CAR NK cells may be a safer, more clinically accessible, and cost-effective cellular therapy than autologous CAR T-cells.
  • Based on the demonstrated successful use of a novel SNAP-CAR technology in T-cells, the Company is developing a first-in-class universal allogeneic SNAP-CAR NK cell.
  • "ISCT 2024 is a prestigious gathering renowned for fostering groundbreaking ideas and innovation," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

BioIVT Highlights its Focus on Cell and Gene Therapy in Spring Industry Events

Retrieved on: 
Lundi, mai 6, 2024
International Society, QA/QC, Cell, CGT, Different, Gene, Society, ISCT, Supply chain, Medical device

"At BioIVT, we view cell and gene therapy as a masterpiece in the making with dedicated researchers serving as the artists behind the canvas, and we are proud to provide the essential materials and the spark of inspiration for the next research breakthroughs," said Jain. "Our fit-for-purpose solutions provide flexibility in the supply chain to mitigate risks to our customers' CGT pipeline--from R&D through clinical phases of development. We look forward to networking with the top minds in cell and gene therapy research at ASGCT and ISCT and sharing how BioIVT's team can support their developments."

Key Points: 
  • WESTBURY, N.Y., May 6, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will be attending two leading industry events focused on cell and gene therapy research, developments and breakthroughs.
  • From May 7 – 11, a team from BioIVT will attend the American Society of Gene and Cell Therapy Annual Meeting (ASGCT) in Baltimore and from May 29 – June 1, a team will attend the International Society of Cell and Gene Therapy Annual Meeting (ISCT) in Vancouver, Canada.
  • BioIVT will have a booth at each event detailing the art of cell and gene therapy, which highlights how BioIVT provides researchers with the resources necessary to develop and fuel their next breakthroughs.
  • We look forward to networking with the top minds in cell and gene therapy research at ASGCT and ISCT and sharing how BioIVT's team can support their developments."

Multiply Labs and Wilson Wolf Corporation Collaborate to Automate G-Rex® Bioreactor for Cell Therapy Manufacturing

Retrieved on: 
Jeudi, mai 2, 2024
Software, Research, General Health, Hardware, Robotics, Technology, Other Manufacturing, Clinical Trials, Science, Engineering, Health, Other Science, Manufacturing, International Society, Multiplication, Automation, Cell, Partnership, CGT, Entrepreneurship, Patient, ISCT, Movement, Nutrient, GMP, Cytotherapy, Organization, Fine chemical

Multiply Labs , a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf , an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex ® bioreactors.

Key Points: 
  • Multiply Labs , a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf , an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex ® bioreactors.
  • The ultimate goal is to lower the barriers to widespread accessibility of potentially lifesaving cell and gene therapy drug products.
  • "Our partnership with Wilson Wolf will be pivotal in realizing this future, as their G-Rex® bioreactors are extensively used for cell therapy manufacturing today.
  • Industry estimates suggest this technology could cut typical GMP-level cell therapy manufacturing costs by around 70% per product.